10-year

10-Year Anniversary Promotion (20% off)

Join GuruFocus Premium Membership Now for Only $279/Year

Once a decade discount

Save up to $500 on Global Membership.

Don't Miss It !

Free 7-day Trial
All Articles and Columns »

38 Stocks with Higher Dividends

Within the recent week, 38 companies have raised their dividend distributions - a good number in my view. On the list are again higher capitalized stocks with a solid track record. I talk about General Electric or 3M.

You can find, like each week, a detailed overview about the biggest stocks below. In addition, there is a full list of all stocks and funds linked.

My favorite large cap dividend grower with recent dividend hikes are...

General Electric (GE) has a market capitalization of $276.81 billion. The company employs 305,000 people, generates revenue of $147.359 billion and has a net income of $14.902 billion. General Electric’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $29.339 billion. The EBITDA margin is 19.91 percent (the operating margin is 11.81 percent and the net profit margin 10.11 percent).


Financial Analysis: The total debt represents 60.42 percent of General Electric’s assets and the total debt in relation to the equity amounts to 336.56 percent. Due to the financial situation, a return on equity of 12.24 percent was realized by General Electric. Twelve trailing months earnings per share reached a value of $1.40. Last fiscal year, General Electric paid $0.70 in the form of dividends to shareholders. GE raised dividends by 15.8 percent last week.


Market Valuation: Here are the price ratios of the company: The P/E ratio is 19.59, the P/S ratio is 1.88 and the P/B ratio is finally 2.31. The dividend yield amounts to 3.22 percent and the beta ratio has a value of 1.83.

3M (MMM) has a market capitalization of $92.05 billion. The company employs 87,677 people, generates revenue of $29.904 billion and has a net income of $4.511 billion. 3M’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $7.771 billion. The EBITDA margin is 25.99 percent (the operating margin is 21.68 percent and the net profit margin 15.08 percent). 


Financial Analysis: The total debt represents 17.92 percent of 3M’s assets and the total debt in relation to the equity amounts to 34.55 percent. Due to the financial situation, a return on equity of 26.94 percent was realized by 3M. Twelve trailing months earnings per share reached a value of $6.51. Last fiscal year, 3M paid $2.36 in the form of dividends to shareholders. MMM raised dividends by 34.6 percent last week.


Market Valuation: Here are the price ratios of the company: The P/E ratio is 21.00, the P/S ratio is 3.08 and the P/B ratio is finally 5.35. The dividend yield amounts to 2.50 percent and the beta ratio has a value of 1.14.

Amgen (AMGN) has a market capitalization of $85.99 billion. The company employs 18,000 people, generates revenue of $17.265 billion and has a net income of $4.445 billion. Amgen’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $8.588 billion. The EBITDA margin is 49.74 percent (the operating margin is 32.30 percent and the net profit margin 25.17 percent). 


Financial Analysis: The total debt represents 48.86 percent of Amgen’s assets and the total debt in relation to the equity amounts to 139.19 percent. Due to the financial situation, a return on equity of 22.81 percent was realized by Amgen. Twelve trailing months earnings per share reached a value of $6.32. Last fiscal year, Amgen paid $1.44 in the form of dividends to shareholders. AMGN raised dividends by 29.8 percent last week.


Market Valuation: Here are the price ratios of the company: The P/E ratio is 18.04, the P/S ratio is 4.98 and the P/B ratio is finally 4.52. The dividend yield amounts to 2.14 percent and the beta ratio has a value of 0.59. 

CVS Caremark (CVS) has a market capitalization of $84.35 billion. The company employs 203,000 people, generates revenue of $123.133 billion and has a net income of $3.882 billion. CVS Caremark’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $9.014 billion. The EBITDA margin is 7.32 percent (the operating margin is 5.59 percent and the net profit margin 3.15 percent). 


Financial Analysis: The total debt represents 14.91 percent of CVS Caremark’s assets and the total debt in relation to the equity amounts to 26.07 percent. Due to the financial situation, a return on equity of 10.25 percent was realized by CVS Caremark. Twelve trailing months earnings per share reached a value of $3.61. Last fiscal year, CVS Caremark paid $0.65 in the form of dividends to shareholders. CVS raised dividends by 22.22 percent last week.


Market Valuation: Here are the price ratios of the company: The P/E ratio is 19.41, the P/S ratio is 0.68 and the P/B ratio is finally 2.29. The dividend yield amounts to 1.57 percent and the beta ratio has a value of 0.84. 

Take a closer look at the full table of stocks with recent dividend hikes. The average dividend growth amounts to 18.10 percent and the average dividend yield amounts to 3.14 percent. Stocks from the sheet are valuated with a P/E ratio of 30.16. The average P/S ratio is 4.26 and P/B 3.19.

Related Stock Ticker:

MMM, AMGN, ANDE, ADM, AHT, T, ALV, BCPC, BZT, BMR, AXMT, BA, BMY, CHN, CUBE, CVS, EFR, ENSG, EQR, EFT, FNLC, GE, GNI, HASI, HEI, HST, HEI-A, INGR, MFNC, MTR, MXF, MCO, PFE, PIR, O, UTG, REXI, ROP, SLG, SRC, STAG, UBA, WDR, WASH, ZTS

Monthly Yield Fact Book | Yields Dividend Champions | Yields Dividend Contenders | Yields Dividend Challengers | High-Yield Large Cap | +10% Yielding Stocks |

About the author:

Dividend
I am a private full time investor searching for investments and investment ideas.

Visit Dividend's Website


Rating: 2.6/5 (5 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK